Company Description
ImmunoPrecise Antibodies Ltd., a techbio company, engages in the development of therapeutic antibodies.
It leverages multi-omics modeling and artificial intelligence through a series of proprietary and patented technologies.
The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies.
It is also involved in the development and licensing of antibody discovery platforms and related IP assets.
The company was founded in 1983 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 1983 |
| IPO Date | Jan 3, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Jennifer Bath |
Contact Details
Address: 823 Congress Ave, Suite 300 Austin, Texas 78701 United States | |
| Phone | (800) 620-4187 |
| Website | ipatherapeutics.com |
Stock Details
| Ticker Symbol | IPA |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | CAD |
| CIK Code | 0001715925 |
| CUSIP Number | 45257F200 |
| ISIN Number | CA45257F2008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President and Non-Independent Director |
| Dr. Ilse Roodink | Chief Scientific Officer and Interim General Manager of IPA Europe, Oss |
| Kari Graber | Vice President of Commercial Services |
| Joseph Scheffler | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Mar 28, 2025 | 6-K | Report of foreign issuer |
| Mar 28, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Mar 12, 2025 | 6-K | Report of foreign issuer |
| Feb 24, 2025 | 6-K | Report of foreign issuer |
| Feb 3, 2025 | 6-K | Report of foreign issuer |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Jan 24, 2025 | SCHEDULE 13G/A | Filing |